Matinas BioPharma (MTNB) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 9, 2020 6:30 AM EDTInitiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020
Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis Q1 2020
Management to host conference call today, Monday, March 9th, at 8:00 a.m. ET
BEDMINSTER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE... More
